Patents Assigned to Wyeth LLC
  • Publication number: 20200325441
    Abstract: The invention relates to methods of improving protein production, e.g., large-scale commercial protein production, e.g., antibody production, utilizing a modified fed-batch cell culture method comprising a cell growth phase and a polypeptide production phase. The modified fed-batch cell culture method combines both cell culture perfusion and fed-batch methods to achieve higher titers of polypeptide products. Because the modified fed-batch cell culture method of the invention produces higher polypeptide product titers than fed-batch culture alone, it will substantially improve commercial-scale protein production. The invention also relates to a perfusion bioreactor apparatus comprising a fresh medium reservoir connected to a bioreactor by a feed pump, a recirculation loop connected to the bioreactor, wherein the recirculation loop comprises a filtration device, e.g., ultrafiltration or microfiltration, and a permeate pump connecting the filtration device to a permeate collection container.
    Type: Application
    Filed: June 22, 2020
    Publication date: October 15, 2020
    Applicant: Wyeth LLC
    Inventor: Gregory Walter HILLER
  • Patent number: 10780160
    Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: September 22, 2020
    Assignee: Wyeth LLC
    Inventors: William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
  • Patent number: 10774117
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: September 15, 2020
    Assignee: Wyeth LLC
    Inventors: Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G. K. Donald, Maninder K. Sidhu, Narender K. Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
  • Patent number: 10729672
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: August 4, 2020
    Assignee: Wyeth LLC
    Inventors: Laurence Moore, Charles Zacharchuk, Sridhar K. Rabindran
  • Patent number: 10716848
    Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: July 21, 2020
    Assignee: Wyeth LLC
    Inventors: William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
  • Publication number: 20200179270
    Abstract: The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.
    Type: Application
    Filed: July 17, 2019
    Publication date: June 11, 2020
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christian Ofslager, Mahdi B. Fawzi, Nataliya Bazhina
  • Publication number: 20200121673
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 23, 2020
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • Patent number: 10603314
    Abstract: The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: March 31, 2020
    Assignees: The General Hospital Corporation, Wyeth LLC
    Inventors: Daniel A. Haber, Daphne Winifred Bell, Jeffrey E. Settleman, Raffaella Sordella, Nadia G. Godin-Heymann, Eunice L. Kwak, Sridhar Krishna Rabindran
  • Patent number: 10596162
    Abstract: The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB 569, HKI-272 and HKI-357.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: March 24, 2020
    Assignees: Wyeth LLC, The General Hospital Corporation
    Inventors: Daniel A. Haber, Daphne Winifred Bell, Jeffrey E. Settleman, Raffaella Sordella, Nadia G. Godin-Heymann, Eunice L. Kwak, Sridhar Krishna Rabindran
  • Patent number: 10597428
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: March 24, 2020
    Assignee: Wyeth LLC
    Inventors: Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G. K. Donald, Maninder K. Sidhu, Narender Kumar Kalyan, Justin Keith Moran, Mark Edward Ruppen, Michael James Flint
  • Patent number: 10588975
    Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: March 17, 2020
    Assignee: Wyeth LLC
    Inventors: Mahdi B. Fawzi, Tianmin Zhu, Syed M. Shah
  • Patent number: 10512681
    Abstract: The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis, and methods related thereto.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: December 24, 2019
    Assignee: Wyeth LLC
    Inventors: Annaliesa Sybil Anderson, Kathrin Ute Jansen, Mark Edward Ruppen, Justin Keith Moran, Susan Kay Hoiseth
  • Patent number: 10507206
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: December 17, 2019
    Assignee: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • Patent number: 10463648
    Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: November 5, 2019
    Assignee: Wyeth, LLC
    Inventors: Eric Joel Benjamin, Wendy Ann Dulin, Yanning Lin, Kai Zhuang
  • Publication number: 20190314365
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 17, 2019
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • Patent number: 10406220
    Abstract: Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naive adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: September 10, 2019
    Assignee: Wyeth LLC
    Inventors: George Rainer Siber, Peter R. Paradiso, Jill Hackell, Stephen Paul Lockhart, William P. Hausdorff
  • Patent number: 10376505
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: August 13, 2019
    Assignee: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • Patent number: 10370424
    Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 6, 2019
    Assignee: Wyeth, LLC.
    Inventors: John Wozney, Howard Seeherman, Christopher Todd Brown
  • Patent number: 10357449
    Abstract: The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: July 23, 2019
    Assignee: Wyeth, LLC
    Inventors: Syed M. Shah, Christian Ofslager, Mahdi B. Fawzi, Nataliya Bazhina
  • Publication number: 20190209688
    Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% glycerin and up to about 10% sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.
    Type: Application
    Filed: March 12, 2019
    Publication date: July 11, 2019
    Applicant: Wyeth LLC
    Inventors: Amanda R. Alley, William A. Bubnis, Stephanie Shield